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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.016S-phase kinase-associated protein 2 (Skp2) functions as the receptor component of the SkpeCullineF-box
complex and is implicated in the degradation of several cell cycle regulators, such as p21Cip1, p27Kip1,
p57Kip2, and cyclin E. Numerous studies in human and experimental tumors have demonstrated low p27Kip1
levels and elevated Skp2 expression. However, a direct association between the inverse correlation of Skp2
and p27Kip1 with tumorigenesis has not been demonstrated. Herein, we provide evidence that skin
tumorigenesis is inhibited in Skp2/ mice. An analysis of mouse keratinocytes indicates that increased
p27Kip1 levels in Skp2/ epidermis cause reduced cell proliferation that is alleviated in the epidermis from
Skp2//p27/ compound mice. In contrast, we establish that a p27Kip1 deﬁciency does not overturn the
reduced skin tumorigenesis experienced by Skp2/ mice. In addition, Skp2/ epidermis exhibits an
accumulation of p53-cofactor CBP/p300 that is associated with elevated apoptosis in hair follicles and
decreased skin tumorigenesis. We conclude that p27Kip1 accumulation is responsible for the hypoplasia
observed in normal tissues of Skp2/ mice but does not have a preponderant function in reducing skin
tumorigenesis. (Am J Pathol 2013, 182: 1854e1864; http://dx.doi.org/10.1016/j.ajpath.2013.01.016)Supported by National Cancer Institute/NIH grant RO1 CA116328
(M.L.R.-P.).
C.S. and S.H.K. contributed equally to this work.The proteasome pathway involves ubiquitin modiﬁcation
and degradation of substrates by the proteasome complex.
The S-phase kinase-associated protein (Skp)eCullineF-box
complex is a ubiquitin ligase that typically contains four
subunits, termed Skp1, Cullin, Ring-ﬁnger protein, and
a member of the large family of F-box adaptor proteins
involved in speciﬁc substrate recognition.1 Skp2 is an F-box
protein that targets several cell cycle regulators for ubiq-
uitination and subsequent degradation.2,3 The speciﬁc
substrates of Skp2 include p21Cip1, p27Kip1, p57Kip2, p130,
Tob1, FOXO1, and c-Myc.4e10 Because most of these
substrates are tumor suppressor proteins, Skp2 has been
classiﬁed as an oncogene. Moreover, Skp2 also suppresses
the p53-dependent apoptosis pathway by antagonizing the
interaction between CBP/p300 and p53.11 Although
multiple substrates for Skp2 have been established, the best
described is p27Kip1.12,13 Accordingly, Skp2 knockout (KO)
mice exhibit high p27Kip1 levels; these mice grow slower
than littermate controls and have smaller organs, with
hypoplastic tissues.14 The ablation of p27Kip1 abolishes allstigative Pathology.
.of the phenotypes observed in the Skp2/ mouse, which
suggests that p27Kip1 is the main target of Skp2.15
Skp2 induces cell proliferation in various experimental
assays, has transforming activity, is found overexpressed in
diverse human cancers, and is, therefore, classiﬁed as an
oncogene.16e18 Presumably, Skp2 expression or improper
temporal expression confers a growth advantage by increasing
p27Kip1 degradation. Moreover, experimental and human
tumors have shown a strong correlation between increased
levels of the Skp2 oncoprotein and diminished p27Kip1 levels,
which suggests that reduced p27Kip1 levels have a prepon-
derant function in tumorigenesis.19,20 Thus, decreased p27Kip1
protein levels are commonly observed in many human
cancers, including epithelial cancers and brain tumors.21
Consequently, high Skp2 and low p27Kip1 levels are indica-
tors for shorter disease-free survival or unfavorable melanoma,
Skp2/p27 Axis in Skin Tumorigenesisbreast, prostate, and lung cancer prognoses.18,22,23 However,
whether the inverse correlation between Skp2 and p27Kip1
protein levels and the association between Skp2 levels and
tumor grade are directly responsible for Skp2 oncogenic
activity has never been addressed.
Our laboratory has previously demonstrated that Myc-
induced keratinocyte proliferation was abolished by the loss
of Skp2 and presumably by the increased level of p27Kip1.24
However, we also observed that Skp2 ablation did not affect
Myc-driven oral tumorigenesis. These ﬁnding suggested
that Skp2 and p27Kip1 are critical for Myc-driven prolifer-
ation, although Myc-mediated tumorigenesis in the oral
epithelium is independent of the Skp2-p27Kip1 axis.24 In this
study, we seek to determine the effect of an Skp2 deﬁciency
on p27Kip1 levels and the rates of keratinocyte proliferation
and skin tumorigenesis. Herein, we show that an Skp2
deﬁciency diminishes ras-mediated skin tumorigenesis that
correlates with p27Kip1 accumulation. Furthermore, we
determined that a p27Kip1 deﬁciency reverses Skp2/
epidermal hypoplasia, but surprisingly, this deﬁciency does
not overturn the reduced skin tumorigenesis that is experi-
enced by the Skp2/ mice. These data provide direct
genetic evidence that p27Kip1 accumulation is responsible
for the reduced keratinocyte proliferation and epidermal
hypoplasia, but not for the reduced number of tumors
observed in the Skp2/ mice. Our data also suggest that
Skp2-mediated apoptosis in the bulge region of hair follicles
(HFs) plays a preponderant role by blocking an early stage
of mouse skin tumorigenesis.
Materials and Methods
Generation of Transgenic Mice
Skp2/ animals were developed as previously described by
Nakayama et al.14 Mice heterozygous for Skp2 (Skp2þ/) on
a C57BL/6 background were bred to generate mice that were
homozygous, heterozygous, or nullizygous for Skp2. The
p27Kip1 heterozygous mice were purchased from The Jackson
Laboratory (Bar Harbor, ME; strain B6.129S4-Cdkn1btm1Mlf)
and crossed back to the genetic background SENCAR for two
generations. Skp2//p27/ compound mice, p27/,
Skp2/, and control wild-type (WT) mice were generated by
crossing p27Kip1 heterozygous mice with Skp2 heterozygous
mice. The p53/ mice on the C57BL/6 background were a
gift from Dr. Robert Smart at North Carolina State University,
Raleigh (TSG-p53; Taconic, Hudson, NY). Skp2//p53þ/
mice and control littermates were generated by breeding
Skp2þ/ with p53þ/ mice.25
Mouse Experiments
For the two-stage carcinogenesis experiment, 3-week-old
Skp2/ mice and WT siblings were initiated with a topical
application of 200 nmol 7,12-dimethylbenz(a)anthracene
(DMBA) in 200 mL of acetone on their dorsal surface. TwoThe American Journal of Pathology - ajp.amjpathol.orgweeks later, themicewere dosed topically twiceweeklywith 4
mg of 12-O-tetradecanoylphorbol-13-acetate (TPA) in 200 mL
of acetone for 30weeks. The tumors were countedweekly and
recorded to determine multiplicity, latency, and incidence.
In the Skp2//p27/ two-stage carcinogenesis experi-
ments, newborn mice were initiated at day 1 after birth with
an application of 50 mg of DMBA in 50 mL of acetone on
their dorsal surface. At day 21, the mice were dosed twice
weekly with 2.5 mg of TPA in 200 mL of acetone for 25
weeks. The skin tumors were counted weekly until the end
of the experiment at 30 weeks. Malignant progression to
squamous cell carcinomas (SCCs) was determined by
macroscopic observation and further conﬁrmed by the
histopathological analysis of parafﬁn-embedded H&E-
stained cross sections.
Western Blot Analyses and Kinase Assays
For immunoblotting, the epidermal tissue was scraped off
with a razor blade, placed into homogenization buffer [150
mmol/L NaCl, 1.0% polyoxyethylene nonylphenol, 0.5%
deoxycholic acid, 0.1% SDS, and 50 mmol/L Tris (pH 8.0)],
and homogenized using a manual homogenizer.26 For
immunoblot analysis of skin tumors, the papillomas were
snap frozen in liquid nitrogen and crushed with a pestle and
mortar. The homogenates were sonicated and centrifuged at
11,000  g at 4C. The supernatants were boiled in 2 mL of
Laemmli sample buffer for Western blot analysis or stored at
80C. The protein concentration was measured with a Bio-
Rad protein assay system (Bio-Rad Laboratories, Richmond,
CA). The protein lysates (25 mg from each sample) were
electrophoresed through 12% acrylamide gels and electro-
phoretically transferred onto nitrocellulose membranes. After
being blocked with 5% nonfat powdered milk in Dulbecco’s
PBS, themembranes were incubated with 1 mg/mL of speciﬁc
antibodies. The following antibodies were used: polyclonal
antibodies against CDK4 (C22), CDK2 (M2), p27Kip1
(M197), p21Cip1 (H164), Puma (G3), p300 (N15), actin (H6),
cyclin A (C19), and cyclin E (C19) (Santa Cruz Biotech-
nology, Santa Cruz, CA), p53 (1C12), and acetylated p53
(Cys379) (Cell Signaling Technology Inc., Boston, MA).
To assess the CDK2 kinase activity, proteins were
extracted and immunoprecipitated in NP40 lysis buffer [Tris
(pH 7.5), 150 mmol/L NaCl, 0.5% NP40, 50 mmol/L NaF,
1 mmol/L Na3VO4, 1 mmol/L dithiothreitol, and 1 mmol/L
phenylmethylsulfonyl ﬂuoride]. To assess the CDK4 kinase
activity, proteins were extracted and immunoprecipitated in
Tween 20 buffer (50 mmol/L HEPES, 150 mmol/L NaCl, 1
mmol/L EDTA, 2.5 mmol/L EGTA, 10% glycerol, 0.1%
Tween 20, 1 mmol/L NaF, 1 mmol/L Na3VO4, and 1 mmol/L
dithiothreitol). Brieﬂy, 250 mg of protein lysates was
immunoprecipitated with 2.5 mg of antibodies against
CDK2 (M-20) or CDK4 (C-22) (Santa Cruz Biotechnology)
for 2 hours at 4C and then incubated with 35 mL of protein
Aeagarose beads. The beads were twice washed in an
immunoprecipitation buffer and a kinase buffer [50 mmol/L1855
Sistrunk et alHEPES (pH 7), 10 mmol/L MgCl2, and 5 mmol/L MnCl2].
Subsequently, 30 mL of kinase buffer, 1 mg of pRb peptide
or histone H1 (EMD Millipore, Billerica, MA) substrate,
5 mCi of [g-32P]ATP (6000 Ci/mmol), 1 mmol/L dithio-
threitol, and 5 mmol/L ATP were added to the bead pellet
and incubated for 30 minutes at 30C. SDS sample buffer
was added. Each sample was boiled for 3 minutes to stop the
reaction and electrophoresed through a polyacrylamide gel.
The Western blot images and kinase assay bands were
quantiﬁed using UN-SCAN-IT gel software version 6.1 for
Windows (Silk Scientiﬁc, Inc., Orem, UT).
Tunnel Assay
Apoptotic cells were determined using TUNEL assays with
the FragEL DNA Fragmentation Detection kit (Colori-
metric-TdT enzyme; Calbiochem, EMB Biosciences Inc.),
following the manufacturer’s instructions. To quantify the
normal and apoptotic cells, the cells were counterstained
with methyl green. Apoptotic keratinocytes in the inter-
follicular and follicular epidermis were quantiﬁed in
sections (1 cm thick). To determine the incidence of
apoptosis in the HFs, HFs that contained at least one
apoptotic cell in the bulge were counted as positive. In all
cases, 12 ﬁelds were counted per section in a total of 10
parafﬁn-embedded sections, which represented ﬁve mice
per genotype.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
Software version 4 (GraphPad Software, San Diego, CA).
Results
Skp2 Deﬁciency Reduces Skin Tumorigenesis
To investigate the function of Skp2 in skin carcinogenesis, we
assessed the response of Skp2/ mice to the two-stage
carcinogenesis protocol. This is a well-suited model for
understanding the multistage nature of tumor progression, in
which tumor initiation is accomplished through a single
topical application of a carcinogen, typically DMBA. This
treatment produces a somatic mutation in the Ha-ras onco-
gene, and tumor promotion occurs when the initiated cells are
expanded through multiple applications of a tumor promoter,
usually TPA, leading to skin papilloma development.
Therefore, Skp2/ and WT littermates were subjected to the
DMBA/TPA regimen for up to 30 weeks, and the incidence
and multiplicity of papillomas were scored weekly. The
incidence of papilloma formation reached a plateau at
approximately 11 weeks, in which 70% to 80% of the WT
mice developed skin tumors. In contrast, a strong reduction
was observed in the Skp2/mice, which reached a plateau of
approximately 20% at 14 weeks of promotion (Figure 1A).
Skp2 deﬁciency also caused a robust decline in the number of1856tumors per mouse (multiplicity). Thirty weeks after the ﬁrst
TPA application, the Skp2/ group exhibited an average of
0.37 papillomas per mouse, whereas the WT mice developed
ﬁve papillomas per mouse (P < 0.001, U-test) (Figure 1B).
The size of the tumors also varied among the genotypes. The
WTpapillomaswere the largest; 85%of tumors exceeded 100
mm3. Conversely, the Skp2/ papillomas were smaller; 16%
of these tumors failed to reach a volume of 30 mm3, and 65%
of the tumors did not surpass 100 mm3 (Figure 1C). Histo-
pathological analysis of the skin tumors collected at 30 weeks
of promotion indicated that all Skp2/ tumors were well-
differentiated papillomas with no atypia in the basal layers.
In brief, 25% of theWT tumors were classiﬁed as moderately
differentiated squamous cell carcinomas (approximately
50% of differentiating cells), and 75% of these tumors were
well-differentiated papillomas (Figure 1, D and E). Compa-
rable to the Skp2/ mouse epidermis,24 a biochemical
analysis of papillomas presented a fourfold increase in
p27Kip1 protein levels, whereas other putative Skp-Cullin-F-
boxSkp2 substrates, such as cyclin E, exhibited no difference
between the Skp2/ and WT papillomas. A mild increase,
although not signiﬁcant, was observed in the level of p21Cip1
in Skp2/ papillomas (Figure 2A). Similar to mouse
epidermis,24 CDK2 kinase activity in Skp2/ papillomas
was comparable to that of WT mice. Moreover, we did not
observe signiﬁcant differences in the CDK4 kinase activity of
WT and Skp2/ tumors (Figure 2B). Collectively, these
observations suggest that a lack of Skp2 expression inmouse
epidermis leads to a relevant increase in p27Kip1 stability in
skin papillomas but has either a minimal or a null effect on
CDK2 and CDK4 kinase activities. Therefore, we conclude
that a lack of Skp2 expression severely affects the onset of
skin tumorigenesis and the proliferative/antiproliferative
balance, which leads to a reduced tumor size. However,
these effects are unlikely to be mediated by the inhibition of
CDK2/CDK4 activities.
Inhibition of Skin Tumorigenesis in Skp2-Null Mice Is
Independent of p27 Accumulation
To evaluate the hypothesis that elevated p27Kip1 protein levels
are associated with reduced tumorigenesis in Skp2/ mice,
we developed Skp2//p27/ compound mice and chal-
lenged this mouse model to the classic DMBA/TPA regimen.
The C57BL/6 mouse genetic background, used in the
previous experiment, is refractory to the initiation-promotion
protocol when TPA is used as a promoter.27 Therefore, the
Skp2//p27/ compound mice were generated on an FVB/
Sencar hybrid background that exhibits higher sensitivity to
the two-stage carcinogenesis protocol.27 As previously re-
ported byNakayama et al,15 the body size of p27/micewas
larger than that of WT siblings, and Skp2/ mice were
smaller than the WT controls, whereas the body size of the
Skp2//p27/ double mutant was similar to that of the WT
controls (Figure 3A). More important, thymus measurements
for each of the four genotypes analyzed conﬁrmed thatajp.amjpathol.org - The American Journal of Pathology
Figure 1 The effect of an Skp2 deﬁciency on induced tumorigenesis in mouse skin. A: Percentage of mice with at least one papilloma (incidence). B: Average
number of papillomas per mouse (multiplicity) within 30 weeks of a biweekly administration of TPA. C: Skin papillomas were classiﬁed according their volume and
expressed as a percentage of the total number of tumors for each genotype. Representative parafﬁn sections of papillomas at 30 weeks of promotion from Skp2 KO
(D) and WT (E) sibling mice. Original magniﬁcation,10. The Skp2-null mice exhibit only moderate dysplasia in a well-differentiated tumor, whereas sections of
the WT papillomas exhibit a marked dysplasia with anaplastic areas.
Skp2/p27 Axis in Skin Tumorigenesisa p27Kip1 deﬁciency partially compensates for the absence of
Skp2 in the Skp2/ affected organs (data not shown). These
data conﬁrm that a p27Kip1 deﬁciency reverses the gross
phenotype observed in the single KO mice.15 Four groups of
mice (Skp2/, p27/, Skp2//p27/, andWTmice) were
treated with DMBA at 3 weeks of age, followed by biweekly
applications of TPA for up to 25weeks, and the incidence and
multiplicity of papillomas were scored in each group for 30
weeks. The incidences of papilloma formation that reached
a plateau at approximately 12 to 13 weeks in the p27/ and
WT mice were 100% and 90%, respectively (Figure 3B). As
expected, the Skp2/ group exhibited a reduction in tumor
incidence, with approximately 60% of mice developing
papillomas byweek 22. Unexpectedly, the absence of p27Kip1
in the Skp2-null background did not overturn the reduced
papilloma incidences that were observed in the Skp2/mice.
In fact, the Skp2//p27/ group reached a plateau of 65% at
12 to 30 weeks (Figure 3B). Moreover, no signiﬁcant differ-
ences were observed in the number of papillomas per mouse
(multiplicity) between the Skp2/ and Skp2//p27/
mice, which developed an average of 4.5 papillomas per
mouse, whereas theWT siblings developed approximately 25
tumors per mouse (Figure 3C). The p27Kip1 deﬁciency did not
affect tumor latency or incidence; however, a signiﬁcant
reduction in tumor multiplicity was observed in the p27/
mice (approximately 10 tumors per mouse) compared with
the WT siblings (Figure 3C). Although it is unclear why the
p27Kip1 deﬁciency leads to fewer papillomas per mouse, we
hypothesize that reduced p27Kip1 levels could compose theThe American Journal of Pathology - ajp.amjpathol.orgassembly of CDK4/D-type cyclin complexes, with a direct
effect in the proliferative balance of the initiated keratinocytes.
These results diverge from those previously reportedbyPhilipp
et al,28 in which the mean number of papillomas did not differ
between the p27/ and control littermates. A further evalua-
tion of mouse skin tumors conﬁrmed that the Skp2/ mice
develop fewer papillomas and that those tumors were smaller
compared with those of the WT mice (Figure 4A). The WT
mice developed signiﬁcantly larger papillomas, in which 50%
of the tumors were >100 mm3, and only 16% of the tumors
were <30 mm3. Conversely, the papillomas from the Skp2/
mice were smaller than those from the other groups: 68% of
the tumors were <30 mm3. More important, although the
incidence and multiplicity values were similar between the
Skp2/ and Skp2//p27/ mice, 40% of papillomas from
the latter group were >100 mm3 (Figure 4A). Therefore, it is
tempting to hypothesize that, in some cases, p27Kip1 deﬁ-
ciency can partially compensate for the absence of Skp2
during the tumor-growing phase, which could cause
a consistent increase in the tumor size, but not during the
initiation stage with the subsequent reduction in the number
of tumors. More important, we determined that approxi-
mately 30% of the Skp2//p27/ papillomas exhibited
a threefold increase in the number of proliferative keratino-
cytes [5-bromo-20-deoxyuridine (BrdU)epositive cells]
compared with the Skp2/ tumors (Figure 4, B and C).
A histopathological analysis of the skin tumors indicated
that 100% of the Skp2/ and Skp2//p27/ tumors were
well-differentiated papillomas with no atypia in the basal1857
Figure 2 Biochemical analysis of cell cycle regulators in papillomas of
Skp2-null and WT mice. A: Immunoblot analysis of WT (Skp2þ/þ) and
Skp2/ papilloma lysates developed with antibodies against Skp2,
p27Kip1, p21Cip1, cyclin A, cyclin E, CDK2, CDK4, and actin (a loading
control). B: CDK4 and CDK2 kinase activities of papillomas from Skp2/
and Skp2þ/þ mice. Fresh tumor lysates were immunoprecipitated with
speciﬁc antibodies against CDKs, and in vitro kinase assays were performed
with pRb or histone H1 peptides as substrates. Con and Skp2þ/þ control
lysates were immunoprecipitated with normal rabbit IgG.
Sistrunk et allayers (Table 1 and Figure 4, E and G). In contrast, 28% of
the WT and 40% of the p27/ tumors were classiﬁed
according to a modiﬁed Broders’ classiﬁcation system29 as
squamous cell carcinoma II, which consisted of moderately
differentiated cells, with 50% of differentiated cells (Table 1
and Figure 4, D and F). More important, 40% of the p27/
tumors were SCC, grade 3 (ie, a poorly differentiated tumor
with little keratinization) (Table 1 and Figures 3A and 4F).
Therefore, similar to the report by Kudo et al,19 our studies
conﬁrmed that the p27/ mice exhibited an increased rate
of malignant progression to SCCs.
We have previously reported that Skp2/ mice devel-
oped a hypoplastic epidermis.24 Therefore, we examined
whether simultaneous ablation of p27Kip1 and Skp2 reversed
the epidermal hypoplasia observed in the Skp2/ mice.24
Consistent with our previous report,24 a histological anal-
ysis of mouse epidermis indicated that a lack of Skp2
expression resulted in a threefold decrease in the number of
proliferative keratinocytes (BrdU label index), along with
a twofold reduction in the number of nucleated cells, which
contributed to the hypoplasia observed in the Skp2/1858epidermis24 (Figure 5, AeF). Ablation of p27Kip1 in the
Skp2-null background overturned the reduced keratinocyte
proliferation and hypoplasia observed in the Skp2/ mice
(Figure 5, AeF). Biochemical analysis of epidermal scrapes
from the Skp2/ and control mice indicated elevated
p27Kip1 protein levels in the Skp2/ mice, with mild or no
modiﬁcations in other putative Skp2 substrates, such as
p21Cip1, cyclin A, or cyclin E (Figure 5G). Moreover, the
Skp2/ epidermis exhibited a threefold reduction in the
CDK4 kinase activity when compared with that of the WT
controls (Figure 5H). More important, a lack of p27Kip1
expression in the Skp2-null epidermis demonstrated
a reversion of CDK4 activity, thereby achieving a level
similar to the WT epidermis (Figure 5H). However, the
increased accumulation of p27Kip1 in the Skp2/ epidermis
had a mild or no effect, reducing the CDK2 kinase activity
compared with that of the WT mice (Figure 5H). As ex-
pected, p27Kip1 ablation greatly increased the CDK2 kinase
activity in mouse keratinocytes, as previously described by
Macias et al30 (Figure 5H). Interestingly, simultaneous
ablation of Skp2 and p27Kip1 greatly increased the CDK2
kinase activity that was observed in the p27/ epidermis
(Figure 5H).
Collectively, these observations suggest that a p27Kip1
deﬁciency reverses the epidermal phenotype that was
observed in Skp2/ mice by increasing the kinase activity
of both CDK4 and CDK2 in mouse keratinocytes. These
data are consistent with previous reports indicating that all
cellular and histopathological abnormalities observed in
Skp2/ mice are abolished in Skp2//p27/ mice.15
Therefore, we provide genetic evidence that p27Kip1 accu-
mulation is responsible for the reduced keratinocyte prolif-
eration and epidermal hypoplasia that was observed in the
Skp2/ mice. Moreover, the inhibition of tumorigenesis
that was observed in the Skp2/ epidermis occurred in
a p27Kip1-independent manner, which suggests that an
ablation of Skp2 initiates additional events that have an
important function during mouse skin tumor initiation.
Skp2 Ablation Is Associated with p53-Dependent
Apoptosis in the Epidermis and Skin Tumorigenesis
Down-regulation of Skp2 decreases cell growth and induces
apoptosis.11,31,32 Therefore, we investigated whether the
ablation of Skp2 induces keratinocyte apoptosis in mouse
epidermis and skin papillomas. Notably, stem cells localized
in the bulge region of HFs retain carcinogen-DNA adducts
after DMBA, which supports the theory that these cells are
responsible for skin tumor initiation.33 Therefore, we ﬁrst
quantiﬁed the number of apoptotic cells within the inter-
follicular epidermis and HFs from the Skp2/ and WT
control mice. We observed a 2.2-fold increase in the rate of
apoptotic cells in the Skp2/ mice compared with WT
control mice (P Z 0.0014, t-test) (Figure 6A). In addition,
the incidence of apoptotic HFs (the percentage of HFs
containing apoptotic cells) was elevated 1.8-fold in Skp2/ajp.amjpathol.org - The American Journal of Pathology
Figure 3 The kinetics of papilloma formation in
Skp2//p27/ compound mice. A: Representative
female Skp2/ (Skp2 KO), Skp2//p27/ (Skp2/p27
KO), p27/ (p27 KO), and WT littermates at 25 weeks of
age. The p27/ mice exhibited an increased malignant
transformation to SCCs (arrow). B: The percentage of WT,
p27/ (p27 KO), Skp2/ (Skp2 KO), and Skp2//p27/
(Skp2/p27 KO) mice with at least one papilloma (inci-
dence). C: Average number of papillomas per mouse
(multiplicity) within 30 weeks of a biweekly administration
of TPA.
Skp2/p27 Axis in Skin Tumorigenesisepidermis compared with that of the WT control mice
(Figure 6B). More important, most of the apoptotic cells
were localized in the bulge region of the HF (Figure 6C),
which suggests that apoptosis may be responsible for
reducing the number of skin tumors observed in the Skp2/
mice. The fact that Skp2/ papillomas are smaller than
those of the WT control mice suggests that apoptosis may
have an important role during the tumor promotion stage.
However, no signiﬁcant differences in the number of
apoptotic cells were observed between the Skp2/ and
WT papillomas (data not shown). Consistent with these
data, another report demonstrated that Skp2 expression
suppresses p53-dependent apoptosis by inhibiting the p53-
p300/CBP interaction.11 Analysis of mouse epidermis
indicated a twofold increase in p300/CBP protein levels
and acetylated-p53 in Skp2/ mice compared with that of
the WT siblings (Figure 6D). Accordingly, Puma, which is
an apoptosis mediator and p53-target gene, increased
fourfold in the Skp2/ epidermis (Figure 6D). Therefore,
we hypothesized that an Skp2 deﬁciency leads to
increased p53-dependent apoptosis in mouse epidermis.
To test this hypothesis, we developed Skp2//p53þ/
compound mice. Evaluation of HF apoptosis showed
a 1.8-fold reduction in the percentage of HFs that con-
tained apoptotic cells in Skp2//p53þ/ mice compared
with Skp2/ mice (P Z 0.045, t-test) (Figure 6E).
Nevertheless, the reduced apoptotic level observed in the
Skp2//p53þ/ mice did not reach the levels that were
detected in the WT siblings. These results suggest that an
Skp2 deﬁciency triggers p53-dependent keratinocyte
apoptosis. However, we cannot exclude the possibilityThe American Journal of Pathology - ajp.amjpathol.orgthat p53-independent mechanisms could also play a rele-
vant function in epidermal apoptosis.
Discussion
As previously noted, the data accumulated recently have
supported the hypothesis that Skp2 has an oncogenic
function, mainly by inducing p27Kip1 degradation. However,
this concept has not been conﬁrmed experimentally. Thus, we
have studied the speciﬁc function of the Skp2/p27Kip1 axis in
a well-known mouse model of chemical carcinogenesis.
We have previously reported that an Skp2 ablation caused
hypoplastic epidermis and reduced keratinocyte prolifera-
tion associated with increased p27Kip1 levels and decreased
CDK4 activity.24 Herein, we examined the skin phenotype
and skin tumorigenesis of Skp2-null mice in the presence or
absence of the Skp2 main substrate, p27Kip1. In agreement
with previous reports demonstrating that a p27Kip1 deﬁ-
ciency restores most of the Skp2/ phenotype,15 we
determined that a p27Kip1 ablation reinstated epidermal
homeostasis and keratinocyte proliferation of Skp2/
epidermis. Biochemical analysis of epidermal scrapes indi-
cated that a p27Kip1 ablation causes increased CDK4 and
CDK2 kinase activities in Skp2//p27/ keratinocytes.
We conclude that p27Kip1 functions as a cell cycle regulator
downstream of Skp2 in mouse keratinocytes. However, we
detected an important difference in mouse hepatocytes14 and
keratinocytes24 on ablating Skp2. Although p27Kip1 accu-
mulation inhibits CDK2 and CDC2 activities in hepato-
cytes, only CDK4 activity was affected in keratinocytes.
Therefore, accumulation of p27Kip1 appears to have an1859
Figure 4 Histopathological analysis and tumor size of the skin papil-
lomas. A: Skin papillomas were classiﬁed according to their volume and
depicted as a percentage of the total number of tumors for the WT, Skp2/
(Skp2 KO), p27/ (p27 KO), and Skp2//p27/ (Skp2/p27 KO) mice.
Immunostaining with anti-BrdU antibody of representative sections of
Skp2/ (B) and Skp2//p27/ (C) papillomas. Representative parafﬁn
sections of papillomas at 30 weeks of promotion from WT (D), Skp2/ (E),
p27/ (F), and Skp2//p27/ (G) mice. Original magniﬁcation, 10.
Skp2/ and Skp2//p27/ mice exhibit only moderate dysplasia in
well-differentiated tumors. A section of a WT papilloma exhibits moderated
dysplasia and some anaplastic areas, whereas severe dysplasia and
anaplastic areas were observed in the p27/ tumors.




No. (%) of tumors classiﬁed
Papilloma* SCC IIy SCC IIIz
WT 18 13 (72) 5 (28) 0 (0)
Skp2/ 22 22 (100) 0 (0) 0 (0)
p27/ 10 2 (20) 4 (40) 4 (40)
Skp2//p27/ 10 10 (100) 0 (0) 0 (0)
*No atypia in the basal layers, basal cell hyperplasia, mild acanthosis and
hyperkeratosis, and no invasion of epidermal cells into the dermis.
yModerately differentiated SCC, with 50% of differentiated cells,
expansion of the basal and spinous layers, and loss of polarity.
zPoorly differentiated SCC, with little keratinization, and cords of
epidermal cells contiguous to the basal layer that are invading the dermis.
Sistrunk et alimportant function in the inhibition of G1/S phase progres-
sion in mouse keratinocytes and S/G2 progression in hepa-
tocytes. Although the molecular mechanisms responsible for
these variances are not understood, these differences can
explain why accumulation of p27Kip1 in mouse hepatocytes
causes polyploidy and multiple centrosomes,14,15 whereas1860those events have not been observed in keratinocytes.
Although the nature of p27Kip1-mediated CDK4 kinase
inhibition has yet to be fully established, recent investiga-
tions have shown that p27Kip1 can bind to and inhibit CDK4
activation by preventing the activating phosphorylation
actions of cyclin HeCDK7, the CDK-activating kinase.34
To determine the effect of Skp2 ablation in skin tumori-
genesis, we used the two-stage carcinogenesis protocol,
which is a well-suited model for understanding the multi-
stage nature of tumor progression. This model allows for the
study of the effect of Skp2 ablation in tumor initiation (an
irreversible genetic alteration in a target cell), tumor
promotion (the process by which an initiated tissue develops
focal proliferation leading to tumor development), and
malignant progression (the ﬁnal transition to invasive
behavior).35 We observed a signiﬁcant reduction in the
number of skin papillomas in Skp2-null mice compared with
WT siblings. Similar to Skp2/ epidermis,24 a biochemical
analysis of Skp2/ papillomas showed increased p27Kip1
levels but no other putative Skp2 substrates, such as p21Cip1,
cyclin E, and cyclin D1. Therefore, we hypothesized that
increased p27Kip1 levels have a major role in inhibiting skin
tumorigenesis. To test this hypothesis, we studied the
kinetics of skin tumor development in Skp2//p27/
compound mice. Contrary to the restoration of normal
phenotype and proliferation observed in mouse epidermis,
a p27Kip1 deﬁciency did not reinstate the number of tumors
in Skp2//p27/ mice. We observed a relevant reduction
in the number of skin papillomas per mouse (multiplicity)
and tumor incidence in both Skp2/ and Skp2//p27/
mice. The number of skin tumors is affected by the number
of initiated cells and/or other early events, such as the clonal
expansion of initiated cells. Therefore, our results provide
genetic evidence that initiation and/or clonal expansion of
initiated cells strongly depends on Skp2 expression but not
on its main substrate, p27Kip1.
Substantial evidence has suggested that cells from the
bulge area of HFs have characteristics of stem cells, such as
slow-cycling, label-retaining properties and high prolifera-
tive capacity.36 In this regard, Morris et al33 demonstrated
that HF stem cells also retain carcinogen-DNA adducts,
which supports the concept that these are target cells duringajp.amjpathol.org - The American Journal of Pathology
Figure 5 Histopathological and biochemical analyses of mouse
epidermis from Skp2//p27/ compound mice. Representative parafﬁn
sections of skin from WT (A), Skp2/ (B), p27/ (C), and Skp2//p27/
(D) mice were stained with H&E. Quantiﬁcation of nucleated cells (E) and
BrdU stained (F) in the epidermis of WT, Skp2/ (Skp2 KO), p27/ (p27
KO), and Skp2//p27/ (Skp2KO/p27KO) mice. G: Epidermal lysates were
separated by SDS-PAGE and transferred onto a nitrocellulose membrane.
Primary antibodies against p27Kip1, p21Cip1, cyclin A, and cyclin E were used
for immunoblot analysis. Actin was used as a loading control. H: CDK2 and
CDK4 kinase activities from the epidermis of the four genotypes were
analyzed. Fresh epidermal lysates were immunoprecipitated with speciﬁc
antibodies against CDKs, and in vitro kinase assays were performed with pRb
or histone H1 peptides as substrates.
Figure 6 Histopathological and biochemical analyses of mouse
epidermis from Skp2//p53þ/ mice. A: Apoptosis in interfollicular
epidermis and HF. B: The percentage of HFs with at least one apoptotic cell
in the bulge area was analyzed by the TUNEL assay. C: Apoptotic kerati-
nocyte (arrow) in the HF of Skp2/ mice. The boxed area in the left
panel corresponds to a higher-magniﬁcation (original magniﬁcation, 20)
image in the right panel. D: Epidermal lysates were separated by SDS-PAGE
and transferred onto a nitrocellulose membrane. Primary antibodies against
p53, acetylated p53, p300, and Puma were used for immunoblot analysis.
Actin was used as a loading control. E: The percentage of HFs with at least
one apoptotic cell in the bulge area in the epidermis of WT, Skp2/ (Skp2
KO), and p53þ//Skp2/ (p53þ/ SKP2 KO) mice. A vertical line was
depicted in blots of D to denote rearrangements of the lines.
Skp2/p27 Axis in Skin Tumorigenesischemical initiation. More important, we observed an
elevated number of apoptotic cells in the interfollicular
epidermis and HFs of Skp2/ mice. Moreover, Skp2/
mice exhibited an increased incidence of apoptotic cells in
the bulge area of HFs. These results suggest that a lack of
Skp2 expression leads to programmed cell death of the HF
stem cells, which affects tumor initiation (or an early event
during skin tumorigenesis). Consistent with our data, Skp2
inhibition by siRNA decreases cell growth and increases
apoptosis.31,37
Biochemical analysis of Skp2/ mouse epidermis
showed increased levels of p300/CBP protein and increased
p53 acetylation, which is essential for p53 activation.38
Consistent with these results, we found an increased level
of Puma, which is a p53 target and pro-apoptotic regulator,
in Skp2/ epidermis. Kitagawa et al11 have reported that
Skp2 antagonizes the interaction between p300/CBP and
p53, which leads to diminished p53 acetylation and furtherThe American Journal of Pathology - ajp.amjpathol.orgsuppresses the transactivation ability of p53. Therefore, our
data suggest that an Skp2 deﬁciency favors p300/CBP-
mediated p53 acetylation, which leads to elevated p53-
mediated apoptosis in HF stem cells and a reduction in
tumorigenesis. To test this hypothesis, we developed Skp2//
p53þ/ mice and determined the incidence of apoptosis in
HFs. Supporting our hypothesis, a reduced p53 dosage caused
a twofold decrease in the percentage of HFs that contained
apoptotic cells on an Skp2-null background. However, the fact
that we did not observe a full reversion of HF apoptosis led us
to hypothesize that a lack of Skp2 expression also induced
p53-independent apoptosis in HFs. However, we cannot
exclude the possibility that the partial decrease in HF
apoptosis is because we used a mouse model that expressed
half of the normal p53 level in mouse epidermis. Notably,
Skp2//p53/ mice were born at a low rate, and this
observation impeded the analysis of the epidermis phenotype
at the same ages as the control mice (7 weeks). Furthermore,
Skp2 inhibits p53 activities in additional pathways. In
particular, studies by Song et al39 have identiﬁed RassF1a as
a speciﬁc target of Skp2. RassF1a inhibits Mdm2 through1861
Sistrunk et alstimulation of Mdm2 self-ubiquitination, leading to p53 acti-
vation.10 In addition, Rassf1a also induces apoptosis through
the activation and translocation of p73, which increases the
transcription of the pro-apoptotic protein, Puma.40 Therefore,
Skp2 can inhibit p53 by preventing CBP/p300 acetylation
activation and by increasing levels of Mdm2 by inhibiting
Rassf1a, thereby yielding two independent pathways to inhibit
apoptosis. More important, our studies also demonstrate that
an Skp2 deﬁciency causes an accumulation of RassF1a in
mouse epidermis (C. Sistrunk and M. Rodriguez-Puebla,
unpublished data) and a reduction of Mdm2 protein levels.
These ﬁndings suggest that the RassF1a pathway can also
accelerate p53-dependent apoptosis in mouse epidermis.
Whether a synergistic effect exists between p300/CBP-
mediated p53 activation and RassF1a pathways warrants
further investigation.
To determine the effect of disrupting the Skp2/p27Kip1
axis in tumor promotion and malignant progression, we
performed histopathological analyses of skin tumors from
Skp2//p27/ and control sibling mice. We determined
a clear reduction in the tumor size of Skp2/ papillomas
that was partially restored in Skp2//p27/ papillomas.
Therefore, we infer that an Skp2 deﬁciency inhibits early-
stage tumorigenesis. However, the few Skp2//p27/
tumors that avoid this early blockage grow more rapidly
compared with Skp2/ papillomas. Therefore, we hypoth-
esize that p27Kip1 ablation favors fast keratinocyte prolif-
eration during the tumor promotion stage of a fraction of the
Skp2//p27/ papillomas, which causes a partial rescue in
tumor volume. Consistent with this hypothesis, we observed
elevated keratinocyte proliferation in approximately 30% of
the Skp2//p27/ papillomas compared with Skp2/
tumors. We also evaluated the relevance of the apoptotic
proﬁle displayed in the papillomas from the four genotypes.
However, we did not observe signiﬁcant differences among
them (data not shown). Therefore, our results suggest that
initiation, and not the promotion stage of skin carcinogen-
esis, was affected by the apoptosis that was induced by an
Skp2 deﬁciency.
Histopathological analysis of the skin tumors indicated
that, although the tumorigenesis blockages in animals
devoid of Skp2 are independent of p27Kip1 accumulation,
p27/ animals developed more aggressive tumors that
were classiﬁed as SCCs. The fact that lack of p27Kip1
expression causes elevated CDK4 and CDK2 kinase activ-
ities suggests that the CDK inhibitor role of p27Kip1 plays
important functions during malignant progression. Sup-
porting this theory, CDK4 overexpression in K5CDK4
transgenic mice also induces malignant progression medi-
ated by the sequestration of p27Kip1 and p21Cip1 by D-type
cyclin/CDK4 complexes.41 Moreover, a lack of CDK2
expression reduces the malignant progression to SCCs in
K5CDK4/CDK2/ mice.42 It is not clear why p27/ mice
showed a reduction in the number of papillomas per mouse
compared with the WT siblings. However, we hypothesize
that an ablation of p27Kip1 compromises the assembly of1862active CDK4/D-type cyclin complexes that, in this case, rely
on the presence of p21Cip1.43
More important, an ablation of Skp2 appears to block
malignant progression in Skp2//p27/ mice because all of
the Skp2/ and Skp2//p27/ tumors were classiﬁed as
well-differentiated papillomas. Notably, an analysis of the skin
tumors from Skp2//p27/, Skp2/, p27/, andWTmice
did not show a signiﬁcant difference in the number of apoptotic
cells (data not shown). Therefore, onemay conclude that Skp2-
regulated inhibitory pathways other than apoptosis impede
malignant progression. Supporting this concept, aberrant
oncogene signals initiate a senescence response in Skp2-null
cells through a p19ARF-p53eindependent pathway,44 and
chemical inhibition of Skp2 activity causes cell death through
activation of autophagy.45
In summary, our data demonstrate that Skp2 inhibition
causes blockage of an early event during themultistage process
of nonmelanoma skin tumorigenesis through a p27Kip1-inde-
pendent pathway. We also suggest that Skp2-mediated inhi-
bition of p53-dependent apoptosis has an important function in
the elevated apoptosis observed in Skp2/ HF stem cells,
which correlates with fewer papillomas. In addition, a partial
rescue of keratinocyte proliferation has been observed in
Skp2//p27/ papillomas, which suggests that cell prolif-
eration during the promotion stage is partially dependent on the
p27Kip1 level.Whether the variations in the effects of Skp2 and
p27Kip1 levels at speciﬁc stages of tumorigenesis are unique for
epidermal tumors warrants further investigation. Finally,
although a strong inverse correlation between Skp2 and
p27Kip1 levels has been demonstrated in numerous experi-
mental and human tumors, Skp2 is also a p27Kip1-independent
indicator of poor prognosis in other human tumors, such as
biliary tract carcinoma,46 soft tissue sarcomas,47 and urinary
tract transitional cell carcinoma.48 Therefore, our results
support the hypothesis that molecular targets of Skp2, other
than p27Kip1, may also be important factors in cancer patho-
genesis. Moreover, a combination of Skp2 and targets, other
than p27Kip1, in addition to the individual molecular targets,
might be useful prognostic factors of cancer.Acknowledgments
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